<DOC>
	<DOC>NCT00851266</DOC>
	<brief_summary>This is a first in man study evaluating the tolerability and immunogenicity of BIPCV/IMX (V512) at increasing concentrations of influenza viral peptides A/M2+B/HA0 peptides and IMX, a saponin-based adjuvant.</brief_summary>
	<brief_title>A Study of a Bivalent Influenza Peptide Conjugate Vaccine in Healthy Adults</brief_title>
	<detailed_description />
	<mesh_term>Influenza, Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subject is in good physical health Subject is not in the category of individuals recommended by the CDC to receive influenza vaccine for the upcoming 2 influenza seasons Subject agrees not to seek vaccination with licensed influenza vaccines during the study Female subjects agree to use acceptable birth control for 6 weeks prior to first dose of vaccine until 1 month post Dose 3 Subject has a history of allergic reaction to the vaccine components Subject has has a fever within 3 days of screening Subject had a vaccination with an inactive virus within 14 days of Dose 1 Subject had a vaccination with a live virus within 30 days of Dose 1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>